Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Effect of anti-il-2r alpha antibody on il-2-induced jak/stat signaling

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Tkaczuk, J.
  • Yu, C. L.
  • Baksh, S.
  • Milford, E. L.
  • Carpenter, C. B.
  • Burakoff, S. J.
  • McKay, Dianne

publication date

  • January 2002

journal

  • American Journal of Transplantation  Journal

abstract

  • Acute allograft rejection is driven by production of cytokines such as interleukin-2 (IL-2) that activate and expand alloreactive T cells by ligating high-affinity IL-2 receptors composed of three subunit chains: alpha, beta, gamma The alpha chain, expressed only on activated T cells, has become an important therapeutic target. Monoclonal antibodies (mAbs) that bind IL-2Ralpha chains significantly decrease transplant rejection. We examined the ability of the humanized anti-IL-2Ralpha antibody daclizumab to block high-affinity IL-2Rs and interrupt T-lymphocyte signaling. Our evaluation focused on a pathway critical for T-cell proliferation, the Jak/STAT pathway. Daclizumab markedly inhibited phosphorylation of the Jak1, Jak3 and STAT5a/b components of the IL-2R-dependent pathway. Suppression by daclizumab was associated with internalization of IL-2Ralpha but not IL-2Rbetagamma chains. High IL-2 doses overcame daclizumab-induced blockade of Jak/STAT phosphorylation despite absent cell surface highaffinity IL-2Rs. Under these circumstances, IL-2-mediated Jak/STAT pathway activation might be generated through residual intermediate affinity IL-2Rbetagamma receptors, and this was demonstrated by complete blockade of signaling when anti-IL-2Rbeta monoclonal antibody was added. Humanized antibodies are an important part of strategies to induce alloantigen tolerance. Understanding the molecular events associated with their beneficial clinical effect is critical to design of future immunosuppressive strategies.

subject areas

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antigens, CD
  • Cells, Cultured
  • DNA-Binding Proteins
  • Humans
  • Immunoglobulin G
  • Interleukin-2
  • Interleukin-2 Receptor alpha Subunit
  • Lymphocyte Activation
  • Lymphocytes
  • MAP Kinase Signaling System
  • Microscopy, Confocal
  • Milk Proteins
  • Phosphorylation
  • Phosphotyrosine
  • Receptors, Interleukin
  • Receptors, Interleukin-2
  • STAT5 Transcription Factor
  • Trans-Activators
  • Tumor Suppressor Proteins
scroll to property group menus

Research

keywords

  • IL-2
  • Jak
  • daclizumab
  • intracellular signaling
  • monoclonal antibody
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1600-6135

Digital Object Identifier (DOI)

  • 10.1034/j.1600-6143.2002.020107.x

PubMed ID

  • 12095053
scroll to property group menus

Additional Document Info

start page

  • 31

end page

  • 40

volume

  • 2

issue

  • 1

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support